CYT-100 / Cytovia Therap - LARVOL DELTA

Preclinical characterization of CYT-100 iPSC derived NK cells alone and in combination with CYT-303 NK cell engager for hepatocellular carcinoma (HCC). (SITC 2022) - "The cytotoxicity of this iNK product is further enhanced by combination with the NK cell engager antibody CYT-303. These data support further development of the combination of iNK cells and NKEs as therapeutics for HCC."

Combination therapy • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CXCR3 • GPC3 • NCAM1 • PTPRC • STAT5

Cytovia Therapeutics Presents New Data on TALEN Gene-Edited iNK Cells and GPC3-Targeted Flex-NK Bispecific Antibodies at 2022 SITC Annual Meeting (PRNewswire) - "The presentations show that Cytovia's allogeneic iNK cell product CYT-100 demonstrated increased time-dependent killing of Hep3B tumor spheroids and sensitivity to cytokine activation & expansion potential. Cytovia's GPC3-targeted bispecific antibody CYT-303 demonstrated potent ADCP and CDC against Hep3B tumors as well as Hep3B tumor spheroid and serial killing activities in the presence Cytovia's allogeneic iNK cell product CYT-100 and PBNKs in a dose-dependent manner. Preclinical pharmacokinetics and safety study results in monkeys fully support CYT-303 clinical development....The data shows that iNK cells edited with an IL-15 knock-in and TGFβR2 knock-out result in enhanced antitumor activity. The editing and manufacturing process will enable clinical evaluation of these product candidates, both alone in combination with CYT-303."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Cytovia Therapeutics To Present New Data on TALEN Gene-Edited iNK Cells and GPC3-Targeted Flex-NK Cell Engagers at 2022 SITC Annual Meeting (PRNewswire) - "Cytovia Therapeutics...announced today that it will be presenting new preclinical data for its TALEN® gene-edited, iPSC-derived NK cells and GPC3-targeted Flex-NK™ cell engager antibodies at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022) taking place in Boston, MA, and virtually November 8-12th, 2022."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Empowering Natural Killer Cell Therapeutics to Fight Cancer (PRNewswire) - "Cytovia plans to focus on multiple milestones, including: Filing the first two INDs for Flex-NK™ CYT-303 and iNK CYT-100; Initiating Phase I/II clinical trials to evaluate CYT-303 and CYT-100, alone and in combination, for the treatment of HCC; Obtaining and presenting initial clinical data for CYT-303 and CYT-100 in HCC; Filing INDs for CYT-150 and CYT-503 and initiating Phase I/II clinical trials."

Clinical data • IND • New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor